A World Beyond
The Longevity Hearing: Session Transcript
The Longevity Hearing: Session Transcript
Orbis Assembly Subcommittee on Bioethics and Longevity Policy. Session 4, 14.06.45. Uncorrected transcript. Three expert witnesses, three different sets of numbers.
CHAIR: This session is called to order. We have three expert witnesses before us today to present evidence on the efficacy and societal impact of current lifespan extension technologies. Witnesses have been instructed to limit opening statements to ten minutes. Dr. Amara Osei, representing the VitaGene Consortium — you have the floor.
DR. OSEI (VitaGene): Thank you, Chair. VitaGene technology targets the underlying mechanisms of cellular ageing — telomere maintenance, mitochondrial repair, epigenetic reset. Our clinical data, drawn from a longitudinal study of 12,000 participants over fifteen years, demonstrates an eighty percent extension in healthspan for recipients who began treatment before the age of fifty.
Eighty percent. That is not a projection. That is measured outcome. Participants in the treatment group show biological markers consistent with individuals twenty to thirty years younger than their chronological age. The control group — matched for socioeconomic status, baseline health, and environmental factors — aged at the standard rate.
I want to be clear about what this means. A healthy forty-year-old who begins VitaGene therapy can expect to live, in full health, to the equivalent of a biological age of sixty-five — but that biological age will not be reached until their chronological age is well past one hundred. They gain decades of healthy life. Decades.
CHAIR: Thank you, Dr. Osei. Dr. Idris Okonkwo — CyberGen Alliance.
DR. OKONKWO (CyberGen): I will not dispute Dr. Osei's data. I will contextualise it. VitaGene extends healthspan — but healthspan is not lifespan. At some point, even repaired cells reach the Hayflick limit. Even reset epigenomes accumulate errors. The eighty percent figure describes early-stage outcomes. Long-term follow-up suggests the real-world efficacy is closer to sixty-five percent.
But my purpose today is not to critique VitaGene. It is to present an alternative approach.
CyberGen does not repair biology. It replaces it. Modular organ systems, neural interfaces, synthetic blood. When a component fails, you replace it. When a system degrades, you upgrade it. The question is not how long you can keep the original parts running — it's whether the original parts were ever the right solution.
Our data: recipients of full CyberGen augmentation show a seventy-two percent reduction in age-related mortality across all causes. The metric is different from VitaGene's — we measure survival, not healthspan — but the outcome is comparable. You live longer. You live differently. You live with components that can be maintained indefinitely.
The sixty-five percent figure Dr. Osei attributed to us is not an efficacy rate. It is the proportion of our recipients who choose not to augment further after the initial procedure. Some stop because they are satisfied. Some stop because they are uncomfortable with how much of their original body remains. That is not a failure of technology. That is a preference.
CHAIR: Dr. Rhea Varma — independent researcher, natural-origin advocacy.
DR. VARMA (Independent): I am not here to present a technology. I am here to present a critique.
Dr. Osei claims eighty percent efficacy. Dr. Okonkwo claims seventy-two percent mortality reduction. Both figures come from studies funded by organisations with a financial interest in positive outcomes. Independent re-analysis of the VitaGene data, conducted by my research group, puts the healthspan extension at forty-five percent — not eighty. The discrepancy arises from differences in how "healthspan" is defined, how the control group is selected, and how dropouts are handled.
The CyberGen data is harder to evaluate because the technology is proprietary. The seventy-two percent figure has not been independently verified. The sample is self-selected — people who choose augmentation are not representative of the general population. They are healthier, wealthier, and more motivated to maintain their health. That introduces bias.
I am not saying these technologies do not work. I am saying we do not know how well they work, because the data we have is produced by the people selling them. If this subcommittee wants a reliable answer, it should fund an independent, longitudinal, multi-technology study — controlled for selection bias, dropout rates, and definitional differences — before making policy decisions based on industry-provided numbers.
CHAIR: Thank you, all three. We will now move to questions.
Appendix — Leaked Internal Study (AXYZ Longevity Division, 2044)
Excerpt. Classification: Confidential. Recovered from anonymous source.
Preliminary results from AXYZ's cross-technology comparison study (n=8,000, five-year follow-up):
| Technology | Effective Healthspan Extension | Notes |
|---|---|---|
| VitaGene (current generation) | 52% ± 6% | Lower than industry claim. Margin consistent with independent re-analysis. |
| CyberGen (full augmentation) | 61% ± 11% | Higher variance due to individual differences in augmentation packages. |
| SomnusTech (hibernation) | N/A (time-shifted) | Does not extend healthspan. Extends calendar lifespan by skipping time. |
| Natural-origin control | 0% (baseline) | — |
Compiler's note: This study was not presented at the hearing. Its findings differ from all three witness testimonies.
This story is part of the A World Beyond Here & Now anthology.